(0.27%) 5 075.75 points
(0.15%) 38 048 points
(0.38%) 17 726 points
(0.13%) $82.80
(1.87%) $1.744
(0.05%) $2 389.70
(0.28%) $28.48
(-0.65%) $948.00
(-0.03%) $0.936
(-0.12%) $10.98
(-0.12%) $0.802
(0.00%) $94.06
@ $24.14
Issued: 14 Feb 2024 @ 12:18
Return: -24.52%
Previous signal: Feb 12 - 15:20
Previous signal:
Return: -4.60 %
Live Chart Being Loaded With Signals
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...
Stats | |
---|---|
Today's Volume | 269 324 |
Average Volume | 225 241 |
Market Cap | 512.24M |
EPS | $0 ( 2024-04-03 ) |
Last Dividend | $0.188 ( 2023-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.86 |
ATR14 | $0.0300 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Kelley Erika K. | Buy | 0 | |
2024-02-20 | Minor Glenda J | Buy | 95 | Class A Common Stock |
2024-02-20 | Sutherlin Michael W | Buy | 406 | Class A Common Stock |
2024-02-20 | Shoemaker Leslie L | Buy | 43 | Class A Common Stock |
2024-02-20 | Jahnke David L | Buy | 515 | Class A Common Stock |
INSIDER POWER |
---|
-78.69 |
Last 94 transactions |
Buy: 7 552 389 | Sell: 18 343 130 |
Volume Correlation
Radius Health Inc Correlation
10 Most Positive Correlations | |
---|---|
COUP | 0.943 |
APR | 0.931 |
ICON | 0.929 |
FTDR | 0.921 |
ASTL | 0.92 |
DFH | 0.918 |
CRVL | 0.917 |
KIN | 0.915 |
CLBT | 0.904 |
RMRM | 0.902 |
10 Most Negative Correlations | |
---|---|
ORRF | -0.913 |
SABS | -0.913 |
MMAC | -0.908 |
LUCD | -0.908 |
VIEW | -0.905 |
AMRB | -0.89 |
SGMA | -0.887 |
LCAP | -0.885 |
LGHL | -0.884 |
TRIT | -0.883 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Radius Health Inc Correlation - Currency/Commodity
Radius Health Inc Financials
Annual | 2023 |
Revenue: | $2.88B |
Gross Profit: | $307.71M (10.68 %) |
EPS: | $-0.920 |
Q4 | 2023 |
Revenue: | $672.90M |
Gross Profit: | $39.48M (5.87 %) |
EPS: | $-0.640 |
Q3 | 2023 |
Revenue: | $717.93M |
Gross Profit: | $90.05M (12.54 %) |
EPS: | $-0.920 |
Q2 | 2023 |
Revenue: | $809.61M |
Gross Profit: | $95.93M (11.85 %) |
EPS: | $0.480 |
Financial Reports:
No articles found.
Radius Health Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.188 (N/A) |
$0.188 (N/A) |
$0.188 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.188 | 2023-04-21 |
Last Dividend | $0.188 | 2023-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-27 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $0.563 | -- |
Avg. Dividend % Per Year | 0.60% | -- |
Score | 3.79 | -- |
Div. Sustainability Score | 8.22 | |
Div.Growth Potential Score | 5.24 | |
Div. Directional Score | 6.73 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.564 | 1.80% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00339 | 1.500 | 9.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00556 | 1.200 | 9.81 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0111 | 1.500 | -0.988 | -1.482 | [0.1 - 1] |
payoutRatioTTM | 2.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.927 | 0.800 | 5.36 | 4.29 | [1 - 3] |
quickRatioTTM | 0.883 | 0.800 | 9.51 | 7.61 | [0.8 - 2.5] |
cashRatioTTM | 0.0132 | 1.500 | -1.038 | -1.557 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.81 | -8.71 | [0 - 0.6] |
interestCoverageTTM | 2.18 | 1.000 | -0.303 | -0.303 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.55 | 2.00 | 7.82 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.095 | 2.00 | 9.45 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.501 | -1.500 | 7.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0989 | 1.000 | -1.685 | -1.685 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0117 | 1.000 | -1.766 | -1.766 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.392 | 1.000 | 8.93 | 8.93 | [0.2 - 2] |
assetTurnoverTTM | 1.639 | 0.800 | 2.41 | 1.926 | [0.5 - 2] |
Total Score | 8.22 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 51.07 | 1.000 | 4.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0111 | 2.50 | -0.635 | -1.482 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.095 | 2.00 | 9.64 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.98 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.55 | 2.00 | 7.82 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.919 | 1.500 | 7.20 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0602 | 1.000 | -0.994 | 0 | [0.1 - 0.5] |
Total Score | 5.24 |
Radius Health Inc
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators